Pneumonia vaccine is under clinical development by SK Bioscience and currently in Phase II for Pneumonia. According to GlobalData, Phase II drugs for Pneumonia have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pneumonia vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pneumonia vaccine overview
Pneumococcal pneumonia vaccine is under development for the treatment of pneumonia. It is a conjugate vaccine. It is administered through intramuscular as a liquid formulation. It is a new chemical entity.
SK Bioscience overview
SK Bioscience, a subsidiary of SK Chemicals Co Ltd, is a biotechnology company that develops and manufactures vaccines for infectious diseases. It offers injection solutions and medicines to prevent diphtheria, tetanus, hepatitis B, pertussis, meningococcal, human papillomavirus, measles, mumps and rubella; and syringes to administer vaccines. The company is also investigating vaccines against COVID-19, herpes zoster, varicella and influenza disease. SK Bioscience utilizes cell line and genetic engineering, mammalian cell culture and glycol-conjugation platform technologies to develop vaccines. It provides process development, up-stream, down-stream and assay development, clinical batch production, scale-up study and process validation, manufacturing, project development and other related services. The company operates a research and development center and manufacturing plant in South Korea. SK Bioscience is headquartered in Seongnam, Gyeonggi, South Korea.
For a complete picture of Pneumonia vaccine’s drug-specific PTSR and LoA scores, buy the report here.